New pneumonia vaccine put to the test in babies
NCT ID NCT07406347
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This early-stage study tests a new pneumococcal vaccine (Pn-MAPS30plus) in 60 healthy infants to see if it is safe and what side effects it may cause. Babies will receive three doses starting around 2 months old, followed by a booster at 12-15 months. The study compares the new vaccine to an existing one (PCV20) and focuses on reactions like tenderness, fever, and irritability.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA, BACTERIAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI could outsmart bacteria: a smarter way to choose antibiotics?
- Does the setting of care affect whether kids finish their antibiotics?
- Inhaled antibiotics aim to beat pneumonia in ECMO patients
- Which works better: one antibiotic or two for this superbug?
- One-Hour test could revolutionize pneumonia treatment in hospitals
- Are hidden immune defects causing your recurring infections? new study investigates.